ALX Oncology Holdings Inc. (ALXO)Healthcare | Biotechnology | South San Francisco, United States | NasdaqGS
2.00 USD
-0.05
(-2.439%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.00 |
Hot Take ↕ | Aug. 22, 2026, 5:39 a.m. EDT
The fundamental reality here is catastrophic. The stock has erased 97.4% of its value over the last five years, with four consecutive years of negative annual returns. Despite a recent headline about beating estimates and promising breast cancer data, the financials tell a different story: negative free cash flow, negative operating cash flow, and a return on equity of nearly -80%. The balance sheet is fragile, with debt significantly outweighing equity, and the market has priced this in with a negative forward P/E. While analysts offer a 'strong buy' recommendation with a $4.60 target, this is likely based on binary event risk (a successful trial) rather than sustainable business quality. The short-term rating is merely a 2 because the recent price action shows some stabilization, but the lack of dividends and the severe multi-year decline make this a dangerous speculative vehicle. The options activity confirms this tension: traders are hedging against total loss while hoping for a miraculous spike, but the underlying business fundamentals remain objectively broken. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.104237 |
| MSTL | 0.112563 |
| AutoETS | 0.113745 |
| AutoARIMA | 0.114339 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.295 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.105 |
| Market Cap | 276,553,984 |
| Forward P/E | -3.72 |
| Beta | 0.40 |
| Website | https://www.alxoncology.com |
As of Aug. 22, 2026, 5:39 a.m. EDT: Speculators are positioning for a volatile rebound rather than a steady grind higher. In the near term (August/September), heavy open interest sits at $3 strikes for calls, suggesting a bet on a sharp move away from current lows. However, the January 2027 data reveals a stark divergence: massive put volume and open interest at deep out-of-the-money strikes ($0.50, $1.50) alongside significant call volume at $3.00. This indicates a 'long gamma' strategy where traders are buying protection against a potential collapse while simultaneously betting on a recovery to $3+, reflecting extreme uncertainty about the company's survival versus a speculative turnaround.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.99029124 |
| Address1 | 323 Allerton Avenue |
| All Time High | 117.45 |
| All Time Low | 0.404 |
| Ask | 2.54 |
| Ask Size | 2 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 604,330 |
| Average Daily Volume3 Month | 1,315,564 |
| Average Volume | 1,315,564 |
| Average Volume10Days | 604,330 |
| Beta | 0.398 |
| Bid | 1.44 |
| Bid Size | 2 |
| Book Value | 0.985 |
| City | South San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.0 |
| Current Ratio | 9.709 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.04 |
| Day Low | 1.98 |
| Debt To Equity | 8.105 |
| Display Name | ALX Oncology |
| Earnings Call Timestamp End | 1,778,243,400 |
| Earnings Call Timestamp Start | 1,778,243,400 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,968,200 |
| Earnings Timestamp Start | 1,793,968,200 |
| Ebitda | -82,295,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.815 |
| Enterprise Value | 149,362,992 |
| Eps Current Year | -0.64934 |
| Eps Forward | -0.53804 |
| Eps Trailing Twelve Months | -1.13 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.992 |
| Fifty Day Average Change | 0.008000016 |
| Fifty Day Average Change Percent | 0.0040160725 |
| Fifty Two Week Change Percent | 99.02912 |
| Fifty Two Week High | 2.66 |
| Fifty Two Week High Change | -0.6600001 |
| Fifty Two Week High Change Percent | -0.24812032 |
| Fifty Two Week Low | 0.96 |
| Fifty Two Week Low Change | 1.04 |
| Fifty Two Week Low Change Percent | 1.0833334 |
| Fifty Two Week Range | 0.96 - 2.66 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,594,992,600,000 |
| Float Shares | 94,732,188 |
| Forward Eps | -0.53804 |
| Forward P E | -3.717196 |
| Free Cashflow | -41,156,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 48 |
| Fullday Change | -0.05 |
| Fullday Change Percent | -2.43902 |
| Fullday Price | 2.0 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00892 |
| Held Percent Institutions | 0.84586 |
| Implied Shares Outstanding | 138,276,997 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California. |
| Long Name | ALX Oncology Holdings Inc. |
| Market | us_market |
| Market Cap | 276,553,984 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_301925264 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -80,890,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 282,085,073 |
| Number Of Analyst Opinions | 5 |
| Open | 2.03 |
| Operating Cashflow | -70,778,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 466 7125 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 2.0 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 2.05 |
| Price Eps Current Year | -3.0800507 |
| Price Hint | 4 |
| Price To Book | 2.0304568 |
| Profit Margins | 0.0 |
| Quick Ratio | 9.434 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.42857 |
| Region | US |
| Regular Market Change | -0.05 |
| Regular Market Change Percent | -2.43902 |
| Regular Market Day High | 2.04 |
| Regular Market Day Low | 1.98 |
| Regular Market Day Range | 1.98 - 2.04 |
| Regular Market Open | 2.03 |
| Regular Market Previous Close | 2.05 |
| Regular Market Price | 2.0 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 639,789 |
| Return On Assets | -0.40403 |
| Return On Equity | -0.80647004 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 138,276,997 |
| Shares Percent Shares Out | 0.0551 |
| Shares Short | 7,612,189 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,460,211 |
| Short Name | ALX Oncology Holdings Inc. |
| Short Percent Of Float | 0.061100002 |
| Short Ratio | 7.52 |
| Source Interval | 15 |
| State | CA |
| Symbol | ALXO |
| Target High Price | 6.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.6 |
| Target Median Price | 4.0 |
| Total Cash | 138,228,992 |
| Total Cash Per Share | 1.0 |
| Total Debt | 11,038,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.13 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.80245 |
| Two Hundred Day Average Change | 0.19755006 |
| Two Hundred Day Average Change Percent | 0.10960086 |
| Type Disp | Equity |
| Volume | 639,789 |
| Website | https://www.alxoncology.com |
| Zip | 94,080 |